secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000805928-23-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q1 revenue up 18% to $36.7M; net loss narrows; FDA clears Axoguard HA+
-----------------------------------------------------------------------------

- Net revenue $36.7M (+18% YoY); net loss $7.1M vs $11.5M prior year.
- Adjusted net loss $4.1M ($0.10/share) vs $8.5M ($0.20/share) prior year.
- FDA 510(k) clearance for Axoguard HA+ Nerve Protector; pilot launch Q2, full launch Q3.
- Full-year 2023 revenue guidance reaffirmed at $154M-$159M.
- Cash and investments $44.1M at March 31, down from $55.0M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000049/0000805928-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592823000049/axgn-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000805928-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer